NOVARTIS Stock London S.E.
Stocks
0HKE
CH0012005267
Pharmaceuticals
OTC Markets Traded|
End-of-day quote
Other stock markets
|
||
| - GBX | - |
|
| 07-08 | Lancelot Sweden fell 0.8% in June, BioArctic slid despite Eli Lilly deal | FW |
| 07-07 | US FDA approves Vera's kidney disease drug | RE |
| Market Cap | 285B 250B 230B 213B 404B 27,252B 412B 2,771B 1,077B 13,336B 1,069B 1,045B 46,295B | P/E 2026 * |
21.7x | P/E 2027 * | 18.4x |
|---|---|---|---|---|---|
| Enterprise Value | 317B 278B 256B 237B 449B 30,319B 458B 3,082B 1,198B 14,837B 1,189B 1,163B 51,504B | EV / Sales 2026 * |
5.57x | EV / Sales 2027 * | 5.19x |
| Free-Float |
91.66% | Yield 2026 * |
2.83% | Yield 2027 * | 2.93% |
Last Transcript: NOVARTIS
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 50 | 01/02/2018 | |
Mukul Mehta
DFI | Director of Finance/CFO | - | 16/03/2026 |
Shreeram Aradhye
CTO | Chief Tech/Sci/R&D Officer | 64 | 16/05/2022 |
| Director | Title | Age | Since |
|---|---|---|---|
Nancy Andrews
BRD | Director/Board Member | 67 | 01/01/2015 |
| Director/Board Member | 69 | 01/01/2016 | |
Ton Büchner
BRD | Director/Board Member | 61 | 01/01/2016 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.60% | +2.02% | +56.34% | +168.94% | 1,084B | |
| -1.44% | +3.71% | +69.07% | +65.40% | 634B | |
| -0.75% | +0.67% | +33.18% | +86.52% | 447B | |
| -1.35% | +1.86% | +29.96% | +26.28% | 330B | |
| -0.86% | +2.79% | +37.72% | +40.85% | 295B | |
| -1.31% | -0.26% | -28.18% | -39.82% | 218B | |
| -0.03% | +1.84% | +23.90% | +68.30% | 199B | |
| -0.40% | +7.82% | +22.29% | +82.50% | 169B | |
| -0.08% | +0.71% | -6.13% | -32.31% | 137B | |
| Average | -0.87% | +2.52% | +26.46% | +51.85% | 390.26B | |
| Weighted average by Cap. | -1.15% | +2.55% | +40.50% | +84.95% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 56.87B 49.88B 46.05B 42.55B 80.65B 5,445B 82.27B 554B 215B 2,665B 214B 209B 9,250B | 60.31B 52.9B 48.84B 45.13B 85.54B 5,775B 87.25B 587B 228B 2,826B 226B 222B 9,810B |
| Net income | 14.1B 12.37B 11.42B 10.55B 20B 1,350B 20.4B 137B 53.35B 661B 52.96B 51.8B 2,294B | 15.65B 13.72B 12.67B 11.71B 22.19B 1,498B 22.64B 152B 59.19B 733B 58.76B 57.47B 2,545B |
| Net Debt | 32.03B 28.09B 25.93B 23.96B 45.42B 3,067B 46.33B 312B 121B 1,501B 120B 118B 5,209B | 28.54B 25.03B 23.11B 21.35B 40.47B 2,732B 41.28B 278B 108B 1,337B 107B 105B 4,642B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
- Stock Market
- Stocks
- NOVN Stock
- 0HKE Stock
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
